about
Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesionInfluence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cellsMutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.PARP-1 modulates amyloid beta peptide-induced neuronal damage.Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.Chemopotentiation by PARP inhibitors in cancer therapy.NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving TargetsRecent approaches to improve the antitumor efficacy of temozolomide.Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor GrowthAntitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.Challenging resistance mechanisms to therapies for metastatic melanoma.Neuropilin-1 as Therapeutic Target for Malignant Melanoma.Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.Exploiting Microglial Functions for the Treatment of Glioblastoma.Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression.Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells.Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen.
P50
Q24312933-0D515C31-5331-4F5B-AE94-E5C214707D94Q34009687-452C7096-CDE3-465A-B62F-D5E9C1F68652Q34234110-3B8F6480-829D-4149-97BA-A8318B06773AQ34516867-76A047F1-E889-4AAF-9E65-046314151D7BQ34532469-4395437E-4382-42DC-A18F-79AA2319FAB9Q35004641-48509435-2813-4B4C-B724-A39EC9381EE8Q35110170-E1232CFE-245C-4D4A-A834-418E61C198D8Q36136079-80984EEA-D4B0-4EB4-8CA5-6D633878802DQ36552658-C5AB4640-53E7-40EF-969A-CAD92BD1F656Q36756258-33F10190-0117-46B6-8712-209F36F0B391Q37307055-049938DD-D60B-479C-945E-A1262692654AQ37370405-890DE74B-4EE4-464D-A161-575FE0D958B9Q37421089-6C4755AD-B044-4221-9E31-0D09EA1721F3Q37463406-67DD63F6-82B9-4719-9DA0-24C8A9546305Q37687310-AACBDB6B-36EB-4E52-B88E-E75CB9F0C6A4Q37706584-A31B7275-EB6D-4F27-8C25-1067FE23BD7AQ37935254-CC662011-2FA3-4ABB-88EE-9CC3691E2A54Q38161180-78EF4AEF-8779-44E5-B28F-32BAE4B3BB64Q38532037-BE8DCCB1-AA2C-4CFF-AEF8-80DA0B1E2373Q38705998-A007B469-E56E-4954-BF31-C004C2833D78Q38765219-260CC5D0-EF80-41E0-84FA-3BE8BA19A66FQ38796476-2A9E6EEE-5B8C-4502-83EA-193C42CB33BCQ38828309-08D678B6-BD66-42A2-BA65-4CBE9B59B8B1Q38896939-98220CC8-905B-430D-AD44-C70920209C02Q38928517-BD73818D-B9A6-4E8E-9614-91727D68A758Q38950364-D6E5934A-C617-49A0-BDC2-4B9C9D862794Q39078357-9ECE0F49-E147-4BC5-94F0-3AD6E957D905Q39157632-2CC95AB2-2CF7-41F0-B74F-B3E8AA081B61Q39602310-D391A3E5-F543-44FB-A2A6-B81512DEAC37Q39613028-5CE4C9A0-2B53-486F-803A-DC312A73BBCBQ39650960-783D2BFE-2C30-4658-8783-54A10B524059Q39854209-88E07F8A-1456-422E-AE87-E6866ABCAC77Q39884432-F9EF0654-7D8E-468E-ABA7-D56B5146D539Q40209766-466CE9E6-68FA-4A43-8C41-3A3E0BAE7DABQ40351208-2BB9265D-5235-499B-BC51-57C140BD201EQ40378448-4EB91114-8C5F-48CA-96D4-31BB85E69B49Q40490577-6B9354A9-18CF-4D96-9069-8F721459AB41Q40700534-6714DC7C-DC48-41D2-81E3-D1C7CEB25CD5Q40807059-57590E95-EA6A-4D91-8202-DA7EB02184D7Q41006776-F87E2C1D-0A81-4770-9658-33F9F1C844E9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Grazia Graziani
@ast
Grazia Graziani
@en
Grazia Graziani
@es
Grazia Graziani
@nl
type
label
Grazia Graziani
@ast
Grazia Graziani
@en
Grazia Graziani
@es
Grazia Graziani
@nl
prefLabel
Grazia Graziani
@ast
Grazia Graziani
@en
Grazia Graziani
@es
Grazia Graziani
@nl
P106
P1153
35268329000
P31
P496
0000-0002-0221-768X